Theravance Biopharma Inc

NASDAQ: TBPH
$8.10
+$0.04 (+0.5%)
Closing Price on September 27, 2024

TBPH Chart and Intraday Price

TBPH Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, KY
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 454.06M USD
Shares Outstanding 48,100,000
Theravance Biopharma is a biopharmaceutical company focused on developing respiratory medicines primarily for the US and European markets. Its flagship product, YUPELRI, is a once-daily treatment for chronic obstructive pulmonary disease (COPD). The company is also working on Ampreloxetine for neurogenic orthostatic hypotension and TRELEGY for COPD and asthma. Founded in 2013 and headquartered in South San Francisco, California, Theravance Biopharma has partnerships with Pfizer and Viatris for advancing its research and development efforts.

TBPH Articles

Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management.  The billionaire is a value investor in the vein of...
Rich Duprey
Published:

Wednesday's Top Analyst Upgrades and Downgrades: Beyond Meat, Boston Beer, Campbell Soup, Nordstrom, Okta, Owens Corning and Victoria’s Secret
Wednesday's top analyst upgrades and downgrades included Beyond Meat, Boston Beer, Campbell Soup, Nordstrom, Okta, Owens Corning and Victoria’s Secret.
Chris Lange
Published: